
CMYK BioFinance Exchange is a biotech-native investment platform and financial operating system built for the realities of biology — long research cycles, IP-heavy valuations, young and first-time founders, uncertain biological timelines, and multi-stakeholder value spanning founders, patients, the environment, industry, and community.
Generic venture funding was designed for software. Biology is different.
Instead of forcing biology to fit financial products, CMYK BioFinance Exchange designs financial products that fit biology.
It is the invisible financial infrastructure underneath a cluster of biotech and bio-adjacent ventures: fermented botanicals, bio-ingredients, microbiome technologies, urban-microbiome projects, bio-robotics, and eco-inventions.
Tell us what you're building. We'll design your capital stack around your biology, not around a term sheet.
Explore bonds, royalty tokens, and curated biotech SPVs designed for institutional and impact mandates.
Propose a challenge, off-take program, or co-development initiative with our cluster.
Eight purpose-built financial rails, each designed for a specific gap in how biotech and bio-adjacent ventures access capital, protect IP, and grow sustainably. No single rail is mandatory — projects compose the stack they need.
EU ECSP-compliant equity and lending campaigns accessible to retail investors across 27 countries via a licensed ECSP partner. Community SPVs pool small tickets into a single cap-table entry.
CMYK Token (governance and utility), Bio-Revenue Tokens (fractional revenue-stream claims), Science NFTs (milestone-linked IP assets), and Talent Tokens for young scientists. Future-phased, not speculative.
EU-taxonomy-aligned green bonds, milestone-floating Science Bonds (coupon steps down as milestones are verified), and outcome-linked Social Impact Bonds repaid by public bodies on verified results.
On-chain IP registry with timestamped provenance. Smart-contract auto-licensing enables third parties to click-to-license formulations, triggering automatic royalty splits to fractional IP holders.
Automated scanning of EIC, Horizon Europe, InvestEU, and ERDF calls. Offers match alerts, pre-filled eligibility checks, and embedded grant experts. Enables grant stacking so no single instrument bears all risk.
Royalty/IP futures give projects cash now against defined future licensing streams. Governed outcome prediction markets act as information signals. Carbon and biodiversity credit futures for regenerative projects.
Delivered via licensed partner banks: venture-debt-style lines with BRT allocations instead of warrants, working capital revolvers against receivables and the IP registry, and founder-friendly personal banking offers.
Strategic off-take agreements (committed purchase volumes become collateral for bonds). Corporate-in-residence programmes: corporate R&D teams co-develop IP inside the cluster, paying fees and gaining licensing access.
The European Crowdfunding Service Provider (ECSP) regulation enables CMYK — through a licensed ECSP partner — to run compliant equity and lending crowdfunding campaigns across EU member states from a single authorization. A project can run a €1M community round legally accessible to retail investors across 27 countries, with standardized disclosures, escrow, and secondary provisions built in.
ECSP-compliant rounds with standardized EU disclosures and escrow — one authorization covers all 27 member states.
Kickstarter-style rounds for supplements, bioactives, and ingredients — funding development while simultaneously generating real demand data and early customers.
Special Purpose Vehicles pool many small tickets from community investors into a single cap-table entry, keeping founder governance clean while enabling broad participation.
Intellectual property is a biotech venture's most valuable asset — and historically one of the hardest to use as financial collateral. The CMYK IP Blockchain changes that by making IP valued, tradable, and composable.
Records patents, applications, trade secrets, and key data packages with timestamped provenance. Complements — does not replace — national and European patent offices. Builds a continuous, auditable record of IP evolution, licensing, contributors, and revenue flows.
Third parties can click-to-license specific processes or formulations. Payment in fiat or stablecoin automatically triggers royalty splits to all fractional IP holders — instantly, without negotiation delays.
AI models estimate IP value based on comparable deals and citation networks, powering dynamic credit lines backed by live IP valuations. Science becomes spendable collateral.
Milestone-linked digital assets (patent grant, first clinical validation, first commercial deployment) with embedded licensing metadata. They can be pledged as collateral or auctioned to strategic buyers.
EU grant programmes represent billions in non-dilutive capital that remain chronically underutilized in less-connected countries and by first-time founders who don't know where to look. CMYK BioFinance Exchange turns grant access into a platform feature, not a consulting service.
Up to €2.5M in grants plus equity investment up to ~€15M. Designed for deep-tech and life-science ventures with breakthrough potential.
Blended public-private finance products and consortium research grants covering the full R&D-to-market journey.
Regional development funds, often the least-competitive and most underutilized source of non-dilutive capital for biotech clusters.
Combine EIC grants, EIB loans, green bonds, and equity crowdfunding so no single instrument bears all risk — making every instrument safer and cheaper for all parties.
The CMYK grants intelligence layer continuously scans EU, national, and regional calls. It offers automated match alerts, pre-filled eligibility checks, and access to embedded grant experts within the platform.

No exit required. CMYK BioFinance Exchange is designed so that cashflows recycle continuously within the network, funding new projects from the revenue of maturing ones. Each loop strengthens the next.
The flywheel replaces the traditional "raise → build → exit" model with a self-sustaining ecosystem where every project's success creates the conditions for the next project's financing.
Science is too complex to be governed purely by money, and capital is too consequential to be governed purely by scientists. CMYK BioFinance Exchange runs a layered governance model where expertise matches decision type.
Scientists, founders, investors, and community members all hold roles. Weighted voting means scientific expertise counts more on technical questions; financial expertise counts more on capital decisions.
Anti-plutocracy mechanisms prevent any single large stakeholder from dominating decisions. Quadratic voting makes additional votes progressively more expensive, preserving the voice of smaller contributors.
Founders cannot be removed lightly. Pre-investment IP remains theirs. Governance safeguards are embedded specifically to protect young inventors from being diluted out of their own breakthroughs.
The CMYK Token grants voting rights in the DAO, preferential access to services, early access to investment windows, and the ability to earn via peer review and scientific contributions to the platform.
CMYK BioFinance Exchange is built to operate compliantly within EU regulatory frameworks — not despite them. It uses ECSP, MiFID, SFDR, and EU taxonomy rules creatively, not recklessly. The platform itself does not hold a full banking, securities, or investment services license; those functions are delivered via licensed partners.
CMYK BioFinance Exchange itself is structured as a steward-owned or mission-locked entity — profit serves purpose, not the reverse.
Portfolio projects are often structured as public benefit or flexible-purpose companies, with mission lock built into their articles at formation.
Use of ECSP-licensed partners, payment institutions, and carefully scoped MiFID/ESMA-compliant services ensures regulated functions are properly wrapped.
IP pools and internal cross-licensing cooperatives allow portfolio companies to access each other's IP under governed terms — creating consortium value without IP fragmentation.
For genuinely novel instruments, CMYK BioFinance Exchange engages with progressive jurisdictions and EU regulatory sandboxes to experiment responsibly before scaling.
CMYK BioFinance Exchange is built for the 24-year-old chemist who invented a core extraction method and deserves more than a thank-you. It is built for the teenager with a soil regeneration idea. It is built for the patient who should own a piece of what heals them.
Community crowdfunding rounds and product pre-purchase campaigns give patients, users, and local communities genuine equity or revenue-share positions in the ventures whose outputs they consume.
Micro-stakes for peer reviews, advisory contributions, and open data sharing. Talent Tokens give long-term upside to scientists who contributed a key method — with vesting, conversion options, and permanent attribution on-chain.
Structured challenges open to teenagers, students, and early-career scientists. Winning entries receive development funding, mentorship, and a pathway into the cluster's capital rails.
A small, symbolic payout to founders whose projects fail scientifically but behave with integrity — sharing data, publishing negative results, and contributing to collective learning. Failure becomes a shared asset, not a stigma.

CMYK BioFinance Exchange is not a fund with a fixed portfolio. It is a network that compounds.
Every project that joins contributes infrastructure for every other project — and benefits from all infrastructure already built.
Every new project adds to the shared licensing pool, creating more revenue for all IP holders and more collateral for platform-wide credit lines.
More projects mean more comparable data for the AI valuation engine, making IP pricing more accurate and credit decisions faster for everyone.
A larger, diversified portfolio makes green bonds and Science Bonds safer for institutional buyers — lowering the cost of capital across the entire network.
Regulatory trust, institutional relationships, and corporate partnerships all compound with scale — reducing friction for new entrants who join a network that already has standing.
Three pathways in. One platform underneath. Tell us where you're coming from, and we'll show you what's possible.
Apply to the CMYK cluster. Tell us what you're building — a bioactive, a microbiome platform, a bio-robotic system, an eco-invention. We'll design a capital stack that fits your biology, your timeline, and your values.
Explore bonds, royalty tokens, and curated biotech SPVs designed to meet institutional and impact mandates — SFDR-aligned, EU-taxonomy-eligible, and genuinely differentiated from generic VC.
Propose a challenge, structure an off-take agreement, or bring your R&D team into the cluster as a corporate-in-residence. Access the licensing pool. Co-develop the ingredients, methods, and platforms of the next decade.
"Biology doesn't run on quarterly cycles. Now your capital doesn't have to either."

Address: 111B Tsarigradsko Shose, Sofia 1784, Bulgaria
Contact us: gs@cmykspices.com
"A biotech‑native exchange for capital, IP, and collaboration."